Skip to Content
Merck
  • Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex I.

Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex I.

Nature medicine (2013-05-28)
Edward T Chouchani, Carmen Methner, Sergiy M Nadtochiy, Angela Logan, Victoria R Pell, Shujing Ding, Andrew M James, Helena M Cochemé, Johannes Reinhold, Kathryn S Lilley, Linda Partridge, Ian M Fearnley, Alan J Robinson, Richard C Hartley, Robin A J Smith, Thomas Krieg, Paul S Brookes, Michael P Murphy
ABSTRACT

Oxidative damage from elevated production of reactive oxygen species (ROS) contributes to ischemia-reperfusion injury in myocardial infarction and stroke. The mechanism by which the increase in ROS occurs is not known, and it is unclear how this increase can be prevented. A wide variety of nitric oxide donors and S-nitrosating agents protect the ischemic myocardium from infarction, but the responsible mechanisms are unclear. Here we used a mitochondria-selective S-nitrosating agent, MitoSNO, to determine how mitochondrial S-nitrosation at the reperfusion phase of myocardial infarction is cardioprotective in vivo in mice. We found that protection is due to the S-nitrosation of mitochondrial complex I, which is the entry point for electrons from NADH into the respiratory chain. Reversible S-nitrosation of complex I slows the reactivation of mitochondria during the crucial first minutes of the reperfusion of ischemic tissue, thereby decreasing ROS production, oxidative damage and tissue necrosis. Inhibition of complex I is afforded by the selective S-nitrosation of Cys39 on the ND3 subunit, which becomes susceptible to modification only after ischemia. Our results identify rapid complex I reactivation as a central pathological feature of ischemia-reperfusion injury and show that preventing this reactivation by modification of a cysteine switch is a robust cardioprotective mechanism and hence a rational therapeutic strategy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
L-Cysteine hydrochloride monohydrate, JIS special grade, ≥99.0%
Pricing and availability is not currently available.
Sigma-Aldrich
L-Cysteine hydrochloride monohydrate, Wacker Chemie AG, 98.5-101.0%
Pricing and availability is not currently available.
Sigma-Aldrich
L-Cysteine hydrochloride monohydrate, tested according to Ph. Eur.
Pricing and availability is not currently available.
Cysteine hydrochloride monohydrate, European Pharmacopoeia (EP) Reference Standard
Pricing and availability is not currently available.
Sigma-Aldrich
L-Cysteine hydrochloride monohydrate, BioUltra, ≥99.0% (RT)
Pricing and availability is not currently available.
Supelco
L-Cysteine hydrochloride monohydrate, Pharmaceutical Secondary Standard; Certified Reference Material
Pricing and availability is not currently available.
Sigma-Aldrich
L-Cysteine hydrochloride monohydrate, reagent grade, ≥98% (TLC)
Pricing and availability is not currently available.
Sigma-Aldrich
L-Cysteine hydrochloride monohydrate, from non-animal source, suitable for cell culture, meets EP, USP testing specifications
Pricing and availability is not currently available.
SAFC
L-Cysteine
Pricing and availability is not currently available.
Sigma-Aldrich
L-Cysteine, ≥97%, FG
Pricing and availability is not currently available.
Sigma-Aldrich
L-Cysteine, BioUltra, ≥98.5% (RT)
Pricing and availability is not currently available.
Sigma-Aldrich
L-Cysteine, 97%
Pricing and availability is not currently available.
Sigma-Aldrich
L-Cysteine, Wacker Chemie AG, ≥98.0%
Pricing and availability is not currently available.
Supelco
L-Cysteine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Pricing and availability is not currently available.
Sigma-Aldrich
L-Cysteine, from non-animal source, BioReagent, suitable for cell culture, ≥98%
Pricing and availability is not currently available.